2005 Panoramica delle azioni SSY Group Limited, una holding di investimento, ricerca, sviluppa, produce, commercializza e vende vari prodotti farmaceutici a ospedali e distributori nella Repubblica Popolare Cinese e a livello internazionale. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
SSY Group Limited Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per SSY Group Prezzi storici delle azioni Prezzo attuale dell'azione HK$3.45 Massimo di 52 settimane HK$5.20 Minimo di 52 settimane HK$3.26 Beta 0.62 Variazione di 1 mese -7.51% Variazione a 3 mesi -9.92% Variazione di 1 anno -26.60% Variazione a 3 anni -10.85% Variazione a 5 anni -46.01% Variazione dall'IPO 800.00%
Notizie e aggiornamenti recenti
Calculating The Fair Value Of SSY Group Limited (HKG:2005) Dec 19
SSY Group Limited Announces Update on Product Development Dec 16
SSY Group Limited Obtains Approval for Drug Production and Registration for Compound Sodium Acetate and Glucose Injection from National Medical Products Administration of China Dec 02
SSY Group's Glycerol Fructose and Sodium Chloride Injection Approved by China's National Medical Products Administration for Consistency Evaluation Nov 27
Chairman & CEO recently bought HK$3.4m worth of stock Nov 20
Price target increased by 14% to HK$6.38 Nov 07 Vedi altri aggiornamenti
Calculating The Fair Value Of SSY Group Limited (HKG:2005) Dec 19
SSY Group Limited Announces Update on Product Development Dec 16
SSY Group Limited Obtains Approval for Drug Production and Registration for Compound Sodium Acetate and Glucose Injection from National Medical Products Administration of China Dec 02
SSY Group's Glycerol Fructose and Sodium Chloride Injection Approved by China's National Medical Products Administration for Consistency Evaluation Nov 27
Chairman & CEO recently bought HK$3.4m worth of stock Nov 20
Price target increased by 14% to HK$6.38 Nov 07
SSY Group Limited Announces Approval for Drug Production and Registration for Phenylephrine Hydrochloride Injection (1ml:10mg) Nov 05
SSY Group Limited Obtains the Approval for Drug Production and Registration for Cycloserine Capsules (0.25G) from the National Medical Products Administration of China Oct 21
SSY Group Limited Cisatracurium Besilate Receives Approval for Market Registration in China Oct 14
Investor sentiment improves as stock rises 18% Oct 02
Chairman & CEO recently bought HK$4.8m worth of stock Sep 25
Analysts Just Slashed Their SSY Group Limited (HKG:2005) EPS Numbers Sep 09
SSY Group Limited Announces Update on Product Development Sep 09
Chairman & CEO recently bought HK$1.5m worth of stock Sep 04
Consensus EPS estimates fall by 10% Sep 04
Price target decreased by 10% to HK$5.58 Sep 02
SSY Group Limited Announces Update on Product Development Sep 02
First half 2024 earnings released: EPS: HK$0.23 (vs HK$0.21 in 1H 2023) Aug 31
SSY Group's (HKG:2005) Dividend Will Be HK$0.08 Aug 31
First half dividend increased to HK$0.08 Aug 30 SSY Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on 27 September 2024
SSY Group Limited to Report First Half, 2024 Results on Aug 28, 2024 Aug 16
SSY Group Limited Announces Update on Product Development Aug 07
SSY Group Limited's (HKG:2005) P/E Is On The Mark Aug 01
Investor sentiment deteriorates as stock falls 16% Jul 29
SSY Group Limited Announces Update on Product Development Jul 23
SSY Group Limited Announces Update on Product Development Jul 16
SSY Group Limited Announces Update on Product Development Jun 29
SSY Group Limited Announces Update on Product Development Jun 24
SSY Group Limited Obtains Approval for Drug Production and Registration for Esmolol Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China Jun 18
SSY Group Limited Announces Update on Product Development Jun 08 SSY Group Limited Obtains Trelagliptin Succinate Approval for Registration from the National Medical Products Administration of China
SSY Group Limited Announces Update on Product Development May 29
Ssy Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Injection (4Ml:8Mg and 2Ml:4Mg) from National Medical Products Administration of China May 28
Upcoming dividend of HK$0.10 per share May 14
SSY Group (HKG:2005) Is Paying Out A Larger Dividend Than Last Year Apr 29
SSY Group's (HKG:2005) Upcoming Dividend Will Be Larger Than Last Year's Apr 15
SSY Group Limited Provides Update on Product Development Apr 03
SSY Group's (HKG:2005) Shareholders Will Receive A Bigger Dividend Than Last Year Mar 31
SSY Group Limited (HKG:2005) Just Released Its Annual Earnings: Here's What Analysts Think Mar 29
Chairman & CEO recently bought HK$2.5m worth of stock Mar 29
Does SSY Group (HKG:2005) Have A Healthy Balance Sheet? Mar 28
SSY Group Limited, Annual General Meeting, May 17, 2024 Mar 28
Full year 2023 earnings: EPS in line with expectations, revenues disappoint Mar 28
SSY Group Limited Announces Final Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024 Mar 27
SSY Group Limited Announces Update on Product Development Mar 21
SSY Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 16
Here's Why We Think SSY Group (HKG:2005) Is Well Worth Watching Mar 06
SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection (12mg) from the National Medical Products Administration of China Mar 02
SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market Mar 01
SSY Group Limited Receives Approval for Gliclazide Tablet Feb 28
SSY Group Limited Provides Update on Product Development Feb 24
SSY Group Limited Obtains the Approval for Drug Production and Registration for Propofol Medium and Long Chain Fat Emulsion Injection from the National Medical Products Administration of China Feb 19
Calculating The Intrinsic Value Of SSY Group Limited (HKG:2005) Feb 13
SSY Group Limited Announces Update on Product Development Jan 31
SSY Group Limited Provides Update on Product Development Jan 24 SSY Group Limited Appoints Liu Wenjun as Non-Executive Director
Ssy Group Limited Provides Update on Product Development Jan 17
SSY Group Limited Announces Update on Product Development Jan 10
SSY Group Limited Obtains Approval for Drug Production and Registration for Ropivacaine Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China Jan 05
SSY Group Limited's (HKG:2005) Price In Tune With Earnings Dec 29
SSY Group Limited Provides Update on Product Development Dec 27
Chairman & CEO recently bought HK$4.7m worth of stock Dec 06
SSY Group Limited Announces Update on Product Development Dec 01
SSY Group Limited Announces Update on Product Development Nov 23
SSY Group Limited Announces Update on Product Development Nov 10
National Medical Products Administration of China Accepts Application for Phase I Clinical Trial of the SSY Group Limited 'S SYN-045 Nov 09
SSY Group Limited Announces Resignation of Feng Hao as Non-Executive Director, Effective from 1 November 2023 Nov 02
SSY Group Limited Obtains Approvals for Drug Production and Registration for Aminophylline Injection Nov 01
SSY Group Limited Announces Update on Product Development Oct 31
SSY Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Tablets from the National Medical Products Administration of China Oct 27
SSY Group Limited Provides Update on Product Development Oct 26
SSY Group Limited Obtains the Clinical Trial Approval Issued By the National Medical Products Administration of China for Alprostadil Injection Oct 21
SSY Group Limited Obtains the Approval for Drug Production and Registration for Linezolid and Sodium Chloride Injection (300ml) from the National Medical Products Administration of China Oct 18
SSY Group Limited Obtains the Approvals for Drug Production and Registration for Tinidazole Tablets (0.5G) and Ornidazole Tablets (0.5G) from the National Medical Products Administration of China Oct 12
SSY Group Limited Announces Update on Product Development Oct 10
Does SSY Group (HKG:2005) Have A Healthy Balance Sheet? Sep 26
SSY Group Limited Announces Update on Product Development Sep 16
Upcoming dividend of HK$0.07 per share at 3.5% yield Sep 07
SSY Group Limited Announces Update on Product Development Sep 05
Price target decreased by 7.7% to HK$6.09 Sep 05
SSY Group (HKG:2005) Will Pay A Larger Dividend Than Last Year At HK$0.07 Sep 03
SSY Group Limited Provides Update on Product Development Sep 02
If EPS Growth Is Important To You, SSY Group (HKG:2005) Presents An Opportunity Aug 31
First half 2023 earnings released: EPS: HK$0.21 (vs HK$0.19 in 1H 2022) Aug 30
Ssy Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2023, Payable on 27 September 2023 Aug 30
SSY Group Limited Announces Update on Product Development Aug 24
SSY Group Limited to Report First Half, 2023 Results on Aug 29, 2023 Aug 18
SSY Group Limited Obtains Approval for Drug Production and Registration for Stiripentol for Suspension (500Mg and 250Mg) from the National Medical Products Administration of China Jul 28
SSY Group Limited Obtains Approval for Drug Production and Registration for Oseltamivir Phosphate for Suspension Jul 14
Chairman & CEO recently bought HK$8.3m worth of stock Jul 08
SSY Group Limited Provides Update on Product Development Jul 07
SSY Group Limited Announces Update on Product Development Jun 30
Estimating The Intrinsic Value Of SSY Group Limited (HKG:2005) Jun 24
SSY Group Limited Obtains Approval for Drug Production and Registration for Citicoline Sodium Injection from the National Medical Products Administration of China Jun 14
SSY Group Limited Obtains the Approvals for Drug Production and Registration for Urapidil Hydrochloride Injection Jun 03
SSY Group Limited Announces Update on Product Development May 31 Rendimenti per gli azionisti 2005 HK Pharmaceuticals HK Mercato 7D -0.3% -1.9% -0.5% 1Y -26.6% -3.9% 19.9%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: 2005 ha avuto una performance inferiore rispetto al Hong Kong Pharmaceuticals che ha registrato un rendimento -3.9 % nell'ultimo anno.
Rendimento vs Mercato: 2005 ha avuto una performance inferiore al mercato Hong Kong che ha registrato un rendimento 19.9 % nell'ultimo anno.
Volatilità dei prezzi Is 2005's price volatile compared to industry and market? 2005 volatility 2005 Average Weekly Movement 5.3% Pharmaceuticals Industry Average Movement 6.4% Market Average Movement 8.8% 10% most volatile stocks in HK Market 18.6% 10% least volatile stocks in HK Market 4.1%
Prezzo delle azioni stabile: 2005 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale ( 5% ) di 2005 è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda SSY Group Limited, una holding di investimento, ricerca, sviluppa, produce, commercializza e vende vari prodotti farmaceutici a ospedali e distributori nella Repubblica Popolare Cinese e a livello internazionale. L'azienda offre soluzioni per infusione endovenosa, tra cui sacche morbide non in PVC, sacche morbide verticali, flaconi di plastica PP e bottiglie di vetro, nonché iniezioni in fiale. Fornisce anche iniezioni di piccolo volume, preparazioni orali, preparazioni di medicina cinese e preparazioni biologiche, oltre a prodotti farmaceutici sfusi e materiali medici.
Mostra di più SSY Group Limited Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di SSY Group con la sua capitalizzazione di mercato? 2005 statistiche fondamentali Capitalizzazione di mercato HK$10.20b Guadagni(TTM ) HK$1.37b Ricavi(TTM ) HK$6.47b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 2005 Conto economico (TTM ) Ricavi HK$6.47b Costo del fatturato HK$2.95b Profitto lordo HK$3.52b Altre spese HK$2.15b Guadagni HK$1.37b
Ultimi guadagni dichiarati
Jun 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) 0.46 Margine lordo 54.39% Margine di profitto netto 21.11% Rapporto debito/patrimonio netto 47.7%
Come si è comportato 2005 nel lungo periodo?
Vedi performance storica e confronto Dividendi
5.2% Rendimento attuale del dividendo
39% Rapporto di remunerazione
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2024/12/23 19:31 Prezzo dell'azione a fine giornata 2024/12/23 00:00 Guadagni 2024/06/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche SSY Group Limited è coperta da 23 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Derrick Sun BNP Paribas Securities (Asia) Milo Liu BOCOM International Securities Limited Ying Shao BofA Global Research
Mostra 20 altri analisti 
